A study on dermatologists' self-assessment of the efficacy of a 1% selenium disulfide-0.9% salicylic acid -based shampoo for scalp seborrheic dermatitis.

Xi Chen, Jiaxin Li, Yurong Li, Aihua Wei

Abstract read

In one paragraph

Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Clinical application of ozone hydrotherapy combined with scalp complex acid treatment for moderate to severe scalp seborrheic dermatitis.Frontiers in medicine · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xi ChenDepartment of Dermatology, Beijing Tongren Hospital Affiliated to Capital Medical University, No.1, Dongjiaomingxiang Street, Dongcheng District, Beijing, 100005, China.

Jiaxin LiDepartment of Dermatology, Beijing Tongren Hospital Affiliated to Capital Medical University, No.1, Dongjiaomingxiang Street, Dongcheng District, Beijing, 100005, China.

Yurong LiDepartment of Dermatology, Beijing Tongren Hospital Affiliated to Capital Medical University, No.1, Dongjiaomingxiang Street, Dongcheng District, Beijing, 100005, China.

Aihua WeiDepartment of Dermatology, Beijing Tongren Hospital Affiliated to Capital Medical University, No.1, Dongjiaomingxiang Street, Dongcheng District, Beijing, 100005, China. weiaihua3000@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scalp seborrheic dermatitis (SSD) is a common inflammatory condition requiring effective topical treatment options. To evaluate the efficacy and acceptability of a 1% selenium disulfide (SeS2)-0.9% salicylic acid shampoo in treating mild to moderate SSD among dermatologists. 95 dermatologists with mild to moderate SSD used the shampoo thrice weekly for 4 weeks. Symptoms were assessed using Visual Analog Scale (VAS) at baseline, Day 14, and Day 28. After 4-week treatment, severe dandruff cases decreased from 28.4% to 3.2%, with 90.5% participants reporting only mild or no dandruff. VAS scores showed significant improvement in all symptoms (p < 0.01). Product satisfaction reached 88.5%, with 90.5% willing to recommend it clinically. The findings of this study suggest that a shampoo based on 1% selenium disulfide (SeS2) and 0.9% salicylic acid is effective in helping alleviate the symptoms of seborrheic dermatitis (SSD).

Indexed as

Dermatitis, SeborrheicDermatologistsDisulfidesHair PreparationsOrganoselenium CompoundsSalicylic AcidScalp DermatosesAdultFemaleHumansMaleMiddle AgedScalpSelf-AssessmentSeverity of Illness IndexTreatment OutcomeDisulfidesHair PreparationsOrganoselenium CompoundsSalicylic AcidAnti-inflammatoryClinical efficacyDandruffDermatologist self-assessmentSalicylic acidSeborrheic dermatitisSelenium disulfide

Identifiers

PMID40192814

DOI10.1007/s00403-025-04165-3

PMCPMC11976785

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.